niacinamide has been researched along with Minimal Disease, Residual in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aggravated behaviors of hepatocellular carcinoma (HCC) will occur after inadequate thermal ablation." | 1.46 | Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment. ( Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD, 2017) |
| "Insufficient thermal ablation promotes residual tumor progression." | 1.43 | Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model. ( Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL, 2016) |
| "Sorafenib was administered either as prophylaxis in patients considered at very high risk for relapse (n = 6) or at the time of disease recurrence (n = 9)." | 1.42 | Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. ( Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, R | 1 |
| Ma, M | 1 |
| Dong, G | 1 |
| Yao, RR | 1 |
| Li, JH | 1 |
| Zheng, QD | 1 |
| Dong, YY | 1 |
| Ma, H | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Tarlock, K | 1 |
| Chang, B | 1 |
| Cooper, T | 1 |
| Gross, T | 1 |
| Gupta, S | 1 |
| Neudorf, S | 1 |
| Adlard, K | 1 |
| Ho, PA | 1 |
| McGoldrick, S | 1 |
| Watt, T | 1 |
| Templeman, T | 1 |
| Sisler, I | 1 |
| Garee, A | 1 |
| Thomson, B | 1 |
| Woolfrey, A | 1 |
| Estey, E | 1 |
| Meshinchi, S | 1 |
| Pollard, JA | 1 |
| Kong, WT | 1 |
| Cai, H | 1 |
| Tang, Y | 1 |
| Zhang, XL | 1 |
| Wang, WP | 1 |
| Azad, A | 1 |
| Herbertson, RA | 1 |
| Pook, D | 1 |
| White, S | 1 |
| Mitchell, PL | 1 |
| Tebbutt, NC | 1 |
4 other studies available for niacinamide and Minimal Disease, Residual
| Article | Year |
|---|---|
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Pro | 2017 |
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; | 2015 |
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magn | 2016 |
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2009 |